Join our Community
Support ToI and remove all ads
Learn more

ISRAEL AT WAR - DAY 432

Yitzhak Peterburg

Kåre Schultz, CEO and president of Teva. (Courtesy)
October 31, 2017, 10:47 am
Teva’s new CEO Schultz to take post Wednesday
Kåre Schultz will start the job a day before the pharmaceuticals firm releases its third quarter earnings results
By Shoshanna Solomon
The Israeli drug company TEVA Pharmaceutical Industries, in Jerusalem, on August 6, 2017. (Yonatan Sindel/Flash90)
October 8, 2017, 11:26 am
Teva shares plunge as competitors get nod for copycat flagship drug
Tel Aviv drop follows declines in New York last week on the news Mylan will start marketing generic version of Copaxone for multiple sclerosis
By Shoshanna Solomon
In a lab in the Teva Medical Factory in Har Hotzvim, Jerusalem, March 15, 2010. (Nati Shohat/Flash90)
September 18, 2017, 3:51 pm
Teva sells remaining women’s health line in deals totaling $1.38 billion
Together with the sale of Paragard earlier this month, the agreements will yield the drugmaker $2.48 billion to repay debt
By Shoshanna Solomon
An Israeli worker walks by the offices of Israeli pharmaceutical company Teva Industries in Jerusalem, October 11, 2013. (Yonatan Sindel/Flash90)
September 12, 2017, 11:44 am
Teva offloads contraceptive brand for $1.1 billion
With new CEO set to step in, Teva is selling assets to reduce its $30 billion debt and refocus pharma giant on central nervous system and respiratory drugs
By Shoshanna Solomon
An Israeli system engineer keeps watch over a production line at the Teva factory in Jerusalem. (Olivier Fitoussi/Flash90)
August 3, 2017, 6:03 pm
As shares plunge, Teva sees 7,000 layoffs by year’s end
Jerusalem based drugmaker plans to shut plants, slashes dividend on disappointing quarterly results
By Shoshanna Solomon
A general view of TEVA Pharmaceutical Industries in Jerusalem, Israel, October 11, 2013. (Yonatan Sindel/Flash90)
June 11, 2017, 5:53 pm
Teva shares rise in Tel Aviv as migraine results buoy investors
Drug is expected to lessen headache for pharma firm, which is facing stiff competition for its flagship anti-MS treatment Copaxone
By Shoshanna Solomon
A general view of TEVA Pharmaceutical Industries in Jerusalem, Israel, October 11, 2013. (Yonatan Sindel/Flash90)
March 23, 2017, 12:46 pm
Teva said to plan cuts of as many as 6,000 jobs globally
Layoffs, including of workers in Israel, come as drugmaker contends with a drop in profit and high debt, Calcalist reports
By Shoshanna Solomon
Erez Vigodman, former CEO of Teva Pharmaceutical Industries (Miriam Alster/FLASH90)
February 7, 2017, 11:43 am
Teva CEO Vigodman steps down as drugmaker seeks direction
Troubled pharma giant’s board appoints Yitzhak Peterburg interim CEO as it searches for a new chief
By Shoshanna Solomon
Load More
Sign in or Register
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.